stockrow
Friday 6 November 2026
Export QGEN’s income statement to Excel — free account
QIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
50.31
0.55
−1.08%
Follow QGEN
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
11.29% | 11.57% | 11.93% | 11.93% | |
Piotroski F-Score |
7 | 8 | 7 | 7 | |
| 6.32% | 7.10% | 7.10% | 6.99% | ||
ROIC |
7.43% | 6.72% | 6.27% | 6.62% | |
Return on Tangible Assets |
16.51% | 17.65% | 20.35% | 20.48% | |
Average Days of Receivables |
66.20 | 70.31 | 68.97 | 67.75 | |
Free Cash Flow per Share |
2.29 | 2.06 | 1.95 | 2.14 | |
Free Cash Flow |
472.50 | 447.20 | 403.87 | 440.60 | |
Capital Expenditures |
(185.20) | (207.13) | (211.34) | (213.87) | |
| Other line items | |||||
Cash ROIC |
6.33% | 6.85% | 7.18% | 7.60% | |
Accounts Receivable Turnover |
5.74 | 5.56 | 5.69 | 5.42 | |
Accounts Payable Turnover |
9.93 | 10.14 | 10.79 | 9.84 | |
Inventory Turnover |
2.49 | 2.72 | 2.70 | 2.63 | |
Average Days of Payables |
35.76 | 33.55 | 35.79 | 36.36 | |
Days of Inventory on Hand |
138.79 | 139.39 | 141.53 | 143.16 | |
Tax Rate |
(0.20) | (0.13) | (0.12) | (0.11) | |
Research and Development Expense of Revenue |
9.12% | 8.97% | 9.15% | 9.27% | |
Selling, General and Administrative Expense of Revenue |
27.60% | 27.93% | 28.02% | 27.91% | |
Share Based Compensation of Revenue |
2.16% | 2.41% | 2.27% | 2.09% | |
Interest Coverage |
14.17 | 14.01 | 11.75 | 11.30 | |
Operating CF/Net income |
1.62 | 1.54 | 1.53 | 1.60 | |
Depreciation/Fixed assets |
0.22 | 0.21 | 0.22 | 0.22 | |
Capex/Depreciation |
(0.95) | (1.05) | (1.03) | (1.04) | |
Revenue per Share |
10.05 | 9.62 | 10.14 | 10.18 | |
Operating CF per Share |
3.19 | 3.01 | 2.97 | 3.17 | |
Capex per Share |
(0.90) | (0.95) | (1.02) | (1.04) | |
Capex to Sales |
0.09 | 0.10 | 0.10 | 0.10 |
Columns are period end dates · fundamentals updated 25 Oct 2026